Caseware UK (AP4) 2024.0.164 2024.0.164 2024-11-302024-11-302025-05-07Consultancy in respiratory medicinefalsefalse1true2023-11-10false0The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006. 15274558 2023-11-09 15274558 2023-11-10 2024-11-30 15274558 2022-11-10 2023-11-09 15274558 2024-11-30 15274558 c:Director1 2023-11-10 2024-11-30 15274558 d:CurrentFinancialInstruments 2024-11-30 15274558 d:CurrentFinancialInstruments d:WithinOneYear 2024-11-30 15274558 d:ShareCapital 2024-11-30 15274558 d:RetainedEarningsAccumulatedLosses 2024-11-30 15274558 c:OrdinaryShareClass1 2023-11-10 2024-11-30 15274558 c:OrdinaryShareClass1 2024-11-30 15274558 c:OrdinaryShareClass2 2023-11-10 2024-11-30 15274558 c:OrdinaryShareClass2 2024-11-30 15274558 c:OrdinaryShareClass3 2023-11-10 2024-11-30 15274558 c:OrdinaryShareClass3 2024-11-30 15274558 c:OrdinaryShareClass4 2023-11-10 2024-11-30 15274558 c:OrdinaryShareClass4 2024-11-30 15274558 c:OrdinaryShareClass5 2023-11-10 2024-11-30 15274558 c:OrdinaryShareClass5 2024-11-30 15274558 c:FRS102 2023-11-10 2024-11-30 15274558 c:AuditExempt-NoAccountantsReport 2023-11-10 2024-11-30 15274558 c:FullAccounts 2023-11-10 2024-11-30 15274558 c:PrivateLimitedCompanyLtd 2023-11-10 2024-11-30 15274558 e:PoundSterling 2023-11-10 2024-11-30 xbrli:shares iso4217:GBP xbrli:pure

Registered number: 15274558









ROBERT BUTTERY MEDICAL LTD







UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE PERIOD ENDED 30 NOVEMBER 2024

 
ROBERT BUTTERY MEDICAL LTD
REGISTERED NUMBER: 15274558

BALANCE SHEET
AS AT 30 NOVEMBER 2024

2024
Note
£

  

CURRENT ASSETS
  

Debtors: amounts falling due within one year
 4 
42,720

Cash at bank and in hand
  
16,681

  
59,401

Creditors: amounts falling due within one year
 5 
(20,084)

NET CURRENT ASSETS
  
 
 
39,317

TOTAL ASSETS LESS CURRENT LIABILITIES
  
39,317

  

NET ASSETS
  
39,317


CAPITAL AND RESERVES
  

Called up share capital 
 6 
1

Profit and loss account
  
39,316

  
39,317


The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the period in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the profit and loss account in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 



R C Buttery
Director

Date: 7 May 2025

The notes on pages 2 to 4 form part of these financial statements.

Page 1

 
ROBERT BUTTERY MEDICAL LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 30 NOVEMBER 2024

1.


GENERAL INFORMATION

Robert Buttery Medical Ltd is a private company limited by shares and incorporated in England and Wales on 10 November 2023. Its registered address is 2 Barton Road, Cambridge, CB3 9JZ.
The Company's functional and presentational currency is GBP.

2.ACCOUNTING POLICIES

 
2.1

BASIS OF PREPARATION OF FINANCIAL STATEMENTS

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

 
2.2

TURNOVER

Turnover comprises revenue recognised by the Company in respect of healthcare services supplied during the period. This is recognised in relation to when the services are performed. 

 
2.3

DEBTORS

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.4

CASH AND CASH EQUIVALENTS

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.5

CREDITORS

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

 
2.6

DIVIDENDS

Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an annual general meeting.

Page 2

 
ROBERT BUTTERY MEDICAL LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 30 NOVEMBER 2024

2.ACCOUNTING POLICIES (CONTINUED)

 
2.7

TAXATION

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income.

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the balance sheet date, except that:
The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and
Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.

Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the balance sheet date.



3.


EMPLOYEES

The average monthly number of employees, including directors, during the period was 2.





4.


DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

2024
£

Trade debtors
22,479

Other debtors
20,241

42,720


Other debtors comprises a loan to a director. The loan is repayable on demand and interest is charged at the HMRC official rate of 2.25%.

Page 3

 
ROBERT BUTTERY MEDICAL LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 30 NOVEMBER 2024

5.


CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

2024
£

Corporation tax
16,484

Accruals and deferred income
3,600

20,084



6.


SHARE CAPITAL

2024
£
ALLOTTED, CALLED UP AND FULLY PAID


76 Ordinary A shares of £0.01 each
0.76
21 Ordinary B shares of £0.01 each
0.21
1 Ordinary C share of £0.01
0.01
1 Ordinary D share of £0.01
0.01
1 Ordinary E share of £0.01
0.01

1.00


On incorporation the Company allotted all of the above shares at par value. 

 
Page 4